Search Ontology:
ChEBI

N(6)-[H2N-NLFQVVHNSYNRPAYSPG-N-{54-amino-7,10,18,21,29,32,40,43,51,54-decaoxo-3,14,25,36,47-pentakis-[5-({2-[alpha-L-Rhap-(1->3)-beta-D-GlcpO]ethyl}sulfinyl)pentanoyl]-3,6,11,14,17,22,25,28,33,36,39,44,47,50-tetradecaazatetrapentacont-1-yl}]adipamido group

Term ID
CHEBI:132682
Synonyms
  • (1-{[3-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy}-20,31,42,53-tetrakis{5-[(2-{[3-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy}ethyl)sulfinyl]pentanoyl}-3-oxido-8,13,16,24,27,35,38,46,49,57,60,62-dodecaoxo-9-{2-[( L-aspar
  • (1-{[3-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl]oxy}-20,31,42,53-tetrakis{5-[(2-{[3-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranosyl]oxy}ethyl)sulfinyl]pentanoyl}-3-oxido-8,13,16,24,27,35,38,46,49,57,60,62-dodecaoxo-9-{2-[( L-asparaginyl-L-leucy
  • (1-{[3-O-(alpha-L-rhamnosyl)-beta-D-glucosyl]oxy}-20,31,42,53-tetrakis{5-[(2-{[3-O-(alpha-L-rhamnosyl)-beta-D-glucosyl]oxy}ethyl)sulfinyl]pentanoyl}-3-oxido-8,13,16,24,27,35,38,46,49,57,60,62-dodecaoxo-9-{2-[( L-Asn-L-Leu-L-Phe-L-Gln-L-Val-L-Val-L-His-L-A
Definition
An organic group consisting of an H2N-NLFQVVHNSYNRPAYSPG-N-{54-amino-7,10,18,21,29,32,40,43,51,54-decaoxo-3,14,25,36,47-pentakis-[5-({2-[alpha-L-Rhap-(1->3)-beta-D-GlcpO]ethyl}sulfinyl)pentanoyl]-3,6,11,14,17,22,25,28,33,36,39,44,47,50-tetradecaazatetrapentacont-1-yl} group linked to the terminal N of an adipamido group. PMID:27091615 reports several of these being linked to the CRM197 immunogenic carrier protein to form a semisynthetic glycoconjugate.
References
Ontology
ChEBI  ( EBI )
Relationships
is a type of
Phenotype
Phenotype resulting from N(6)-[H2N-NLFQVVHNSYNRPAYSPG-N-{54-amino-7,10,18,21,29,32,40,43,51,54-decaoxo-3,14,25,36,47-pentakis-[5-({2-[alpha-L-Rhap-(1->3)-beta-D-GlcpO]ethyl}sulfinyl)pentanoyl]-3,6,11,14,17,22,25,28,33,36,39,44,47,50-tetradecaazatetrapentacont-1-yl}]adipamido group
Phenotype where environments contain N(6)-[H2N-NLFQVVHNSYNRPAYSPG-N-{54-amino-7,10,18,21,29,32,40,43,51,54-decaoxo-3,14,25,36,47-pentakis-[5-({2-[alpha-L-Rhap-(1->3)-beta-D-GlcpO]ethyl}sulfinyl)pentanoyl]-3,6,11,14,17,22,25,28,33,36,39,44,47,50-tetradecaazatetrapentacont-1-yl}]adipamido group
Phenotype modified by environments containing N(6)-[H2N-NLFQVVHNSYNRPAYSPG-N-{54-amino-7,10,18,21,29,32,40,43,51,54-decaoxo-3,14,25,36,47-pentakis-[5-({2-[alpha-L-Rhap-(1->3)-beta-D-GlcpO]ethyl}sulfinyl)pentanoyl]-3,6,11,14,17,22,25,28,33,36,39,44,47,50-tetradecaazatetrapentacont-1-yl}]adipamido group
Human Disease Model